Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 1996

View Archived Issues

Pharmacia & Upjohn, McGill University claim antiparasitic MAb

Novel diagnostic agents for spongiform encephalopathies reported

New calcimimetic agents from ZymoGenetics

Bayer reveals sugar-modified cytostatic agents

New thrombin inhibitors under study at Merck & Co.

Novo Nordisk claims dopamine D3 receptor ligands for CNS indications

VIP analogs and derivatives claimed for smooth muscle relaxation

Therapeutically active NPY analog reported by academic source

Access in-licenses polymer platinum compounds

InSite Vision completes preliminary clinical trial of ophthalmic drug candidate

Dusa photodynamic therapy advances to phase III

Successful phase III results reported for British Biotech PAF antagonist

British Biotech discontinues development of MMP inhibitor

Another British Biotech compound reaches clinical stage

Medarex bispecific antibody enters phase II in colon cancer patients

MGI Pharma acquires drugs from Ilex Oncology

OsmoCyte approved for marketing in U.S.

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...